Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924727 · ClinicalTrials.gov registry record · Phase 3
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,669
- Enrollment target
NCT02924727: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT02924727 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 5,669 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (634% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02924727, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,669 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
Primary Outcome
A confirmed composite endpoint includes cardiovascular (CV) death, heart failure (HF) hospitalization, or outpatient heart failure
Interventions
- DRUG Ramipril
- DRUG Valsartan
- DRUG Placebo of LCZ696
- DRUG LCZ696 (sacubitril/valsartan)
- DRUG Placebo of ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,669 participants |
| Start Date | 2016-12-09 |
| Est. Completion | 2021-02-26 |
| Phase | Phase 3 |
What the finished NCT02924727 record still lists
NCT02924727 is an interventional study that assigns participants to a tested intervention. Its 5,669 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (634% higher).
The record links to 0 conditions, and to 5 interventions - of which Ramipril is the first listed.
NCT02924727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02924727 about?
NCT02924727 is a clinical study titled "Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI". The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
What is the current status of trial NCT02924727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,669 participants. The study started on 2016-12-09. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT02924727?
The interventions under investigation include: Ramipril (DRUG), Valsartan (DRUG), Placebo of LCZ696 (DRUG), LCZ696 (sacubitril/valsartan) (DRUG), Placebo of ramipril (DRUG).
Who is sponsoring clinical trial NCT02924727?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02924727's enrollment target sits among peer trials
5,669 42nd of 2000 higher than 1,959 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04983875 · 5,708 participants · NA
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
- NCT06627335 · 5,621 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- NCT05636176 · 5,600 participants · Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
- NCT06981598 · 5,586 participants · NA
Prevention of Psychological Health Problems Via Integrated Operational Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI